Theravance Biopharma (NASDAQ:TBPH) Stock Rating Lowered by Zacks Research

Theravance Biopharma (NASDAQ:TBPH) was downgraded by Zacks Research from a “strong-buy” rating to a “hold” rating in a note issued to investors on Monday, Zacks reports.

Several other analysts have also recently commented on TBPH. HC Wainwright cut shares of Theravance Biopharma from a “buy” rating to a “neutral” rating and boosted their price target for the stock from $15.00 to $17.00 in a research note on Tuesday, July 7th. JonesTrading cut Theravance Biopharma from a “buy” rating to a “hold” rating in a report on Monday, June 29th. Weiss Ratings upgraded Theravance Biopharma from a “hold (c)” rating to a “hold (c+)” rating in a research report on Monday, August 17th. BTIG Research lowered Theravance Biopharma from a “buy” rating to a “neutral” rating in a research note on Monday, June 29th. Finally, Wall Street Zen cut Theravance Biopharma from a “buy” rating to a “hold” rating in a report on Saturday, May 16th. Eight equities research analysts have rated the stock with a Hold rating, According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $19.40.

Theravance Biopharma Price Performance

Shares of TBPH opened at $17.06 on Monday. Theravance Biopharma has a 1 year low of $13.08 and a 1 year high of $21.03. The company has a 50 day simple moving average of $16.95 and a two-hundred day simple moving average of $16.49. The firm has a market cap of $885.76 million, a P/E ratio of 16.89 and a beta of 0.25.

Theravance Biopharma (NASDAQ:TBPH) last released its quarterly earnings data on Monday, August 10th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.07 by ($0.18). Theravance Biopharma had a net margin of 51.58% and a negative return on equity of 0.77%. The company had revenue of $20.73 million for the quarter, compared to the consensus estimate of $22.49 million. On average, sell-side analysts anticipate that Theravance Biopharma will post 1.56 earnings per share for the current year.

Insider Transactions at Theravance Biopharma

In other news, major shareholder Eli Samaha sold 37,799 shares of the company’s stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $17.00, for a total transaction of $642,583.00. Following the sale, the insider directly owned 9,174,453 shares in the company, valued at approximately $155,965,701. This represents a 0.41% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Rhonda Farnum sold 13,314 shares of the stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $16.39, for a total transaction of $218,216.46. Following the completion of the transaction, the senior vice president directly owned 232,457 shares of the company’s stock, valued at approximately $3,809,970.23. The trade was a 5.42% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 350,011 shares of company stock worth $6,008,309. Insiders own 7.65% of the company’s stock.

Institutional Investors Weigh In On Theravance Biopharma

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in TBPH. Squarepoint Ops LLC purchased a new position in shares of Theravance Biopharma in the 2nd quarter worth approximately $302,000. Groupe la Francaise purchased a new stake in shares of Theravance Biopharma in the second quarter worth approximately $510,000. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new stake in shares of Theravance Biopharma during the 2nd quarter worth approximately $1,071,000. California State Teachers Retirement System lifted its stake in shares of Theravance Biopharma by 1,550.9% during the 2nd quarter. California State Teachers Retirement System now owns 672,911 shares of the biopharmaceutical company’s stock worth $11,439,000 after acquiring an additional 632,150 shares during the last quarter. Finally, GTS Securities LLC purchased a new position in Theravance Biopharma during the 2nd quarter valued at $430,000. 99.10% of the stock is currently owned by hedge funds and other institutional investors.

About Theravance Biopharma

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.